skip to content »

Center for Cell and Gene Therapy

Houston, Texas

Center for Cell and Gene Therapy
Center for Cell and Gene Therapy
not shown on screen

Robert Krance, M.D.

Robert KranceProfessor and Director
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Director - Managed Care, Texas Children's Cancer Center and Baylor College of Medicine

E-mail: rakrance@txch.org
Phone: 832-824-4661

Education

  • M.D., Loyola University Medical School, Maywood, IL
  • Resident in Pediatrics, Rush Presbyterian St. Luke Medical Center, Chicago, IL
  • Fellow, Pediatric Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN

Research Interests

Bridging the laboratory and clinic, Dr. Krance coordinates the activities of the pediatric bone marrow transplant programs. A major activity of this program focuses on the application of gene transfer to define discrete clinical endpoints in the application of bone marrow and stem cell transplantation. Using gene marking, it has been possible to follow individual cell populations. This application has demonstrated the capacity of harvested marrow to contribute to leukemia relapse and conversely to promote long term hematopoietic repopulation.

Dr. Krance is also interested in the use of stem cell transplantation for the therapy of autoimmune disorders and is the principal investigator on a protocol for patients with multiple sclerosis.

Selected Publications

  • Krance R, Heslop H, Mahmoud H, Ribeiro R, Douglass E, Hurwitz C, Santana V, Kun L, Horowitz MM, Brenner M. Anti-pan T-lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute graft-vs-host disease prophylaxis following allogeneic bone marrow transplantation from HLA-identical sibling donors. Bone Marrow Transplant 11:33-36, 1993.
  • Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85-86, 1993.
  • Mahmoud HH, Hurwitz CA, Roberts WM, Santana VM, Ribeiro RC, Krance RA.Tretinoin toxicity in children with acute promyelocytic leukemia. Lancet 342:1394-1395, 1993.
  • Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana V, Anderson WF, Ihle JN. Gene marking to determine whether autologous marrow infusion restores long-term hemopoiesis in cancer patients. Lancet 342:1134-1137, 1993.
  • Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. Xomazyme-CD5 immunotoxin in conjunction with partial T-cell depletion for prevention of graft rejection and graft versus host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant 13:571-575, 1994.
  • Santana VM, Hurwitz CA, Blakley RL, Crom WR, Luo X, Krance RA. Complete hematologic remissions induced by 2-Chlorodeoyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84:1237-1242, 1994.
  • Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383, 1994.
  • Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13, 1995.
  • Phipps S, Brenner MK, Heslop HE, Krance RA, Jayawardene D, Mulhern R. Psychological effects of bone marrow transplantation on children and adolescents: Preliminary report of a longitudinal study. Bone Marrow Transplant 15:829-835, 1995.
  • Heslop HE, Bensim E, Brenner MK, Krance RA, Stricklin LM, Rochester RA, Billings R. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet 346:805-806, 1995.
  • Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T-lymphocytes. Nature Medicine 2:551-555, 1996.
  • Winer-Muram HT, Gurney JW, Bozeman PM, Krance RA. Pulmonary complications after bone marrow transplantation. Radio1 Clin North Am 34:97-117, 1996.
  • Hongeng S, Krance RA, Bowman LC, Srivastava DK, Cunningham JM, Horwitz EM, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 350:767-771, 1997.
  • Krance RA, Brenner MK. BMT beats autoimmune disease. Nat. Med. 4:153-155, 1998.

E-mail this page to a friend